Levodropropizine Tablets

1. The antitussive effect of levodropropizine: The antitussive effect of levodropropizine on anesthetized guinea pigs and rabbits was studied, and the results showed that levodropropizine has a good antitussive effect. After intravenous injection, the antitussive effect of mechanical and electrical stimulation rabbits and guinea pigs was 1/10 to 1/20 of codeine, which is similar to racemic levodropropizine. After oral administration to guinea pigs, the antitussive effect of levodropropizine on cough caused by gas stimulation was similar to that of levodropropizine and codeine. 2. The antitussive effect of levodropropizine on dogs: The antitussive effect of levodropropizine was studied by oral administration to awake dogs. The results showed that after oral administration of levodropropizine and racemic levodropropizine at 30 and 60 mg/kg, both levodropropizine and racemic levodropropizine could inhibit the cough reflex in a dose-dependent manner. In the test within 45 minutes after drug administration, the high dose (60 mg/kg) of levodropropizine and racemic levodropropizine showed the first antitussive effect 15 minutes after drug administration, and the maximum inhibitory effect on reflexes was 93% and 88%, respectively. The antitussive effect was still obvious 2 hours after drug administration. The low dose (30 mg/kg) of both drugs had obvious antitussive effect and reached the maximum effect 30 minutes after drug administration. The antitussive effect of levodropropizine was 1/20 times that of codeine phosphate. 3. Effect of levodropropizine on afferent C-fibers of the vagus nerve of cats. (1) Levodropropizine is an effective antitussive drug. This study studied its effect on the release of single neurons of the vagus nerve C-fibers of anesthetized cats to explore whether its inhibitory mechanism on vagal C-fibers is involved in the antitussive effect. Vagal C-fibers can be identified by their response to phenylbiguanide (PGB), and recording is performed by placing electrodes at the distal end of the cut vagus nerve. According to the sufficient response to the lungs, C fibers are divided into two categories: lung-related and lung-irrelevant. (2) PBG increases the release of two types of C fibers, excites the respiratory reflex, and causes apnea. This respiratory reflex can be abolished when the second vagus nerve is cut, while the stimulation reflex mediated by PGB is not affected by vagus nerve cut. (3) The response of C fibers to PBG before and after intravenous administration of levodropropizine was compared. Levodropropizine can shorten the duration of apnea and reduce the response of C fibers to PBG. (4) The effects of C fibers on PBG and a mixture of PBG and levodropropizine were compared. The results showed that when levodropropizine was present, the apnea period was shortened and the C fiber release rate was reduced. (5) Levodropropizine reduced the response of C fibers to PBG, with the non-related type reduced by 50% and the non-lung-related type reduced by 25%. The results showed that levodropropizine significantly reduced the response of vagal C fibers to chemical stimulation. Therefore, the antitussive effect of levodropropizine may be mediated by its inhibitory effect on C fibers.

Levodropropizine.

This product is a white film-coated tablet, which appears white after removing the film coating.

This product is suitable for dry cough and persistent cough caused by acute upper respiratory tract infection and acute bronchitis. This product is suitable for dry cough and persistent cough caused by acute upper respiratory tract infection and acute bronchitis.

Oral administration. Adults: 1 tablet (60 mg) each time, 3 times a day.

Adverse reactions are rare, mainly manifested as gastrointestinal reactions, nausea, upper abdominal pain, indigestion, vomiting, diarrhea, central nervous system reactions, fatigue, dizziness, drowsiness, headache, palpitations, dry mouth, etc., occasionally visual impairment, rash, dyspnea are rare. Transient elevation of transaminase can be seen at high doses.

1. Those who are known or may be allergic to this type of drug are prohibited from using this product. 2. Those who have excessive sputum or impaired mucociliary clearance function are prohibited from using this product. 3. Pregnant and lactating women are prohibited from using this product.

Precautions for children: Use with caution in children under 2 years old. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: There is no significant change in the pharmacokinetics of elderly patients, and there is no need to adjust the dosage or change the interval between medications.

1. According to pharmacological studies on experimental animals, this product is rapidly absorbed by the nervous system. 2. It also affects the hypoglycemic effect of insulin and digestive system drugs. 3. For particularly sensitive patients, caution should be exercised when taking inhibitory drugs at the same time. 4. Clinical studies have not found any adverse effects on the simultaneous use of other drugs for the treatment of bronchopneumonia.

Store in sealed, dry place.

60mg

Tentative 12 months

Kunming Yuanrui Pharmaceutical Co., Ltd.

• Founded in:

  1999-12-08

• Address:

  Huashi Road, Yanglin Industrial Development Zone, Yunnan

• Tax NO.:

  91530127719426088A

• Registered Funds:

  20.8125 million yuan

• Website:

  Log in to view

• Email:

  Log in to view